These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21500544)

  • 1. [Metabolic pathways of OGCP and the influence of parkin protein on the metabolism of OGCP].
    Wang CY; Cao L; Tang BS; Zhang HN; Guo JF; Liao SS; Tang JG; Yan XR; Tan LM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):157-60. PubMed ID: 21500544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Protective effect of over-expression OGCP on HEK293 cells treated by rotenone and mutant Parkin protein].
    Wang CY; Tang BS; Zhang HN; Tang JG; Guo JF; Yan XX; Tan LM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):604-8. PubMed ID: 20848778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
    Sha Z; Zhao J; Goldberg AL
    Methods Mol Biol; 2018; 1844():261-276. PubMed ID: 30242715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1.
    Glauser L; Sonnay S; Stafa K; Moore DJ
    J Neurochem; 2011 Aug; 118(4):636-45. PubMed ID: 21615408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
    Watanabe M; Funakoshi T; Unuma K; Aki T; Uemura K
    Toxicology; 2014 Aug; 322():43-50. PubMed ID: 24801902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein damage, repair and proteolysis.
    Chondrogianni N; Petropoulos I; Grimm S; Georgila K; Catalgol B; Friguet B; Grune T; Gonos ES
    Mol Aspects Med; 2014 Feb; 35():1-71. PubMed ID: 23107776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin: same molecule, different degradation pathways.
    Clague MJ; Urbé S
    Cell; 2010 Nov; 143(5):682-5. PubMed ID: 21111229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkin-dependent and -independent degradation of synaptotagmin-11 in neurons and astrocytes.
    Wang Y; Yan S; Zhang F; Li J; Li R; Zhang CX
    Neurosci Lett; 2020 Nov; 739():135402. PubMed ID: 32976921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities.
    Crosas B; Hanna J; Kirkpatrick DS; Zhang DP; Tone Y; Hathaway NA; Buecker C; Leggett DS; Schmidt M; King RW; Gygi SP; Finley D
    Cell; 2006 Dec; 127(7):1401-13. PubMed ID: 17190603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitin-proteasome pathway mediates degradation of APH-1.
    He G; Qing H; Cai F; Kwok C; Xu H; Yu G; Bernstein A; Song W
    J Neurochem; 2006 Dec; 99(5):1403-12. PubMed ID: 17059559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson's disease.
    Korutla L; Furlong HA; Mackler SA
    Neuroscience; 2014 Jan; 257():86-95. PubMed ID: 24231739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
    Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
    Kumar P; Pradhan K; Karunya R; Ambasta RK; Querfurth HW
    J Neurochem; 2012 Feb; 120(3):350-70. PubMed ID: 22098618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turn up the lysosome.
    Saftig P; Haas A
    Nat Cell Biol; 2016 Sep; 18(10):1025-7. PubMed ID: 27684505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial quality control by the ubiquitin-proteasome system.
    Taylor EB; Rutter J
    Biochem Soc Trans; 2011 Oct; 39(5):1509-13. PubMed ID: 21936843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation.
    d'Azzo A; Bongiovanni A; Nastasi T
    Traffic; 2005 Jun; 6(6):429-41. PubMed ID: 15882441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of connexin43 gap junctions involves both the proteasome and the lysosome.
    Laing JG; Tadros PN; Westphale EM; Beyer EC
    Exp Cell Res; 1997 Nov; 236(2):482-92. PubMed ID: 9367633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serine protease HtrA2/Omi cleaves Parkin and irreversibly inactivates its E3 ubiquitin ligase activity.
    Park HM; Kim GY; Nam MK; Seong GH; Han C; Chung KC; Kang S; Rhim H
    Biochem Biophys Res Commun; 2009 Sep; 387(3):537-42. PubMed ID: 19631192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative effects of the ubiquitin-proteasome pathway on glucocorticoid receptor down-regulation and transactivation are mediated by CHIP, an E3 ligase.
    Wang X; DeFranco DB
    Mol Endocrinol; 2005 Jun; 19(6):1474-82. PubMed ID: 15761032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in silico model of the ubiquitin-proteasome system that incorporates normal homeostasis and age-related decline.
    Proctor CJ; Tsirigotis M; Gray DA
    BMC Syst Biol; 2007 Mar; 1():17. PubMed ID: 17408507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.